E
Yield10 Bioscience, Inc.
YTENQ
$0.015
$0.000.00%
E
Sell
5/25/2023Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D- on 5/25/2023 due to a decline in the valuation index, solvency index and growth index. Debt to equity increased from 0.13 to 0.52, the quick ratio declined from 2.72 to 0.8, and total revenue declined 31.03% from $87 to $60.
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D- on 5/25/2023 due to a decline in the valuation index, solvency index and growth index. Debt to equity increased from 0.13 to 0.52, the quick ratio declined from 2.72 to 0.8, and total revenue declined 31.03% from $87 to $60.
D
Sell
3/14/2023Downgrade
Yield10 Bioscience, Inc. (YTENQ) was downgraded to D- from D on 03/14/2023.
Yield10 Bioscience, Inc. (YTENQ) was downgraded to D- from D on 03/14/2023.
D
Sell
2/10/2023Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 2/10/2023 due to an increase in the volatility index.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 2/10/2023 due to an increase in the volatility index.
D
Sell
11/4/2022Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 11/4/2022 due to a decline in the volatility index.
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 11/4/2022 due to a decline in the volatility index.
D
Sell
10/18/2022Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 10/18/2022 due to an increase in the volatility index and growth index. Operating cash flow increased 18.18% from -$3.1M to -$2.54M.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 10/18/2022 due to an increase in the volatility index and growth index. Operating cash flow increased 18.18% from -$3.1M to -$2.54M.
D
Sell
6/1/2022Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 6/1/2022 due to a decline in the total return index and volatility index.
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 6/1/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Yield10 Bioscience, Inc. (YTENQ) was upgraded to D from E+ on 05/16/2022.
Yield10 Bioscience, Inc. (YTENQ) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D on 5/13/2022 due to a noticeable decline in the growth index, solvency index and total return index. Debt to equity increased from 0.03 to 0.04, operating cash flow declined 24.83% from -$2.49M to -$3.1M, and EBIT declined 11.89% from -$2.97M to -$3.32M.
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D on 5/13/2022 due to a noticeable decline in the growth index, solvency index and total return index. Debt to equity increased from 0.03 to 0.04, operating cash flow declined 24.83% from -$2.49M to -$3.1M, and EBIT declined 11.89% from -$2.97M to -$3.32M.
D
Sell
5/4/2022Upgraded
Yield10 Bioscience, Inc. (YTENQ) was upgraded to D from E+ on 05/04/2022.
Yield10 Bioscience, Inc. (YTENQ) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D on 4/20/2022 due to a decline in the growth index, total return index and solvency index. Operating cash flow declined 24.75% from -$1.99M to -$2.49M, earnings per share declined from -$0.4921 to -$0.6104, and the quick ratio declined from 11.16 to 9.34.
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D on 4/20/2022 due to a decline in the growth index, total return index and solvency index. Operating cash flow declined 24.75% from -$1.99M to -$2.49M, earnings per share declined from -$0.4921 to -$0.6104, and the quick ratio declined from 11.16 to 9.34.
D
Sell
11/11/2021Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 11/11/2021 due to an increase in the growth index. Earnings per share increased from -$0.6351 to -$0.4921, and operating cash flow increased 6.87% from -$2.14M to -$1.99M.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 11/11/2021 due to an increase in the growth index. Earnings per share increased from -$0.6351 to -$0.4921, and operating cash flow increased 6.87% from -$2.14M to -$1.99M.
D
Sell
11/8/2021Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
1/7/2021Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 1/7/2021 due to an increase in the volatility index.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 1/7/2021 due to an increase in the volatility index.
D
Sell
12/18/2020Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 12/18/2020 due to a decline in the volatility index.
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 12/18/2020 due to a decline in the volatility index.
D
Sell
12/3/2020Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 12/3/2020 due to an increase in the volatility index and total return index.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 12/3/2020 due to an increase in the volatility index and total return index.
D
Sell
11/18/2020Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 11/18/2020 due to a noticeable decline in the growth index. Total revenue declined 7.69% from $221 to $204, operating cash flow declined 3.37% from -$1.99M to -$2.06M, and EBIT declined 2.67% from -$2.14M to -$2.19M.
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 11/18/2020 due to a noticeable decline in the growth index. Total revenue declined 7.69% from $221 to $204, operating cash flow declined 3.37% from -$1.99M to -$2.06M, and EBIT declined 2.67% from -$2.14M to -$2.19M.
D
Sell
5/18/2020Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 5/18/2020 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from -$12.022 to -$2.1212, operating cash flow increased 28.7% from -$3.21M to -$2.29M, and total revenue increased 27.86% from $140 to $179.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 5/18/2020 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from -$12.022 to -$2.1212, operating cash flow increased 28.7% from -$3.21M to -$2.29M, and total revenue increased 27.86% from $140 to $179.
D
Sell
5/1/2020Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D- from E+ on 5/1/2020 due to an increase in the growth index, volatility index and total return index.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D- from E+ on 5/1/2020 due to an increase in the growth index, volatility index and total return index.
E
Sell
3/27/2020Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D- on 3/27/2020 due to a large decline in the growth index, efficiency index and solvency index. Net income declined 245.26% from -$1.98M to -$6.84M, operating cash flow declined 134.58% from -$1.37M to -$3.21M, and total capital declined 98.39% from $8.46M to $136.
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D- on 3/27/2020 due to a large decline in the growth index, efficiency index and solvency index. Net income declined 245.26% from -$1.98M to -$6.84M, operating cash flow declined 134.58% from -$1.37M to -$3.21M, and total capital declined 98.39% from $8.46M to $136.
D
Sell
3/23/2020Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D- from E+ on 3/23/2020 due to an increase in the volatility index and total return index.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D- from E+ on 3/23/2020 due to an increase in the volatility index and total return index.
E
Sell
3/6/2020Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D- on 3/6/2020 due to a decline in the volatility index and total return index.
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D- on 3/6/2020 due to a decline in the volatility index and total return index.
D
Sell
1/24/2020Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D- from E+ on 1/24/2020 due to an increase in the volatility index.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D- from E+ on 1/24/2020 due to an increase in the volatility index.
E
Sell
1/2/2020Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D- on 1/2/2020 due to a decline in the volatility index, efficiency index and total return index. Total capital declined 19.51% from $10.52M to $8.46M, and net income declined 5.93% from -$1.87M to -$1.98M.
Yield10 Bioscience, Inc. (YTEN) was downgraded to E+ from D- on 1/2/2020 due to a decline in the volatility index, efficiency index and total return index. Total capital declined 19.51% from $10.52M to $8.46M, and net income declined 5.93% from -$1.87M to -$1.98M.
D
Sell
8/8/2017Downgrade
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 8/8/2017 due to a decline in the total return index.
Yield10 Bioscience, Inc. (YTEN) was downgraded to D- from D on 8/8/2017 due to a decline in the total return index.
D
Sell
5/19/2017Upgraded
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 5/19/2017 due to an increase in the total return index, efficiency index and volatility index.
Yield10 Bioscience, Inc. (YTEN) was upgraded to D from D- on 5/19/2017 due to an increase in the total return index, efficiency index and volatility index.
D
Sell
11/25/2016Upgraded
Metabolix, Inc. (MBLX) was upgraded to D- from E+ on 11/25/2016 due to a large increase in the growth index, valuation index and efficiency index. Net income increased 225.83% from -$3.2M to $4.02M, earnings per share increased from -$0.1154 to $0.1444, and total capital increased 107.1% from $4.14M to $8.58M.
Metabolix, Inc. (MBLX) was upgraded to D- from E+ on 11/25/2016 due to a large increase in the growth index, valuation index and efficiency index. Net income increased 225.83% from -$3.2M to $4.02M, earnings per share increased from -$0.1154 to $0.1444, and total capital increased 107.1% from $4.14M to $8.58M.
E
Sell
5/17/2016Downgrade
Metabolix, Inc. (MBLX) was downgraded to E+ from D- on 5/17/2016 due to a large decline in the growth index, valuation index and solvency index. The quick ratio declined from 3.27 to 1.87, operating cash flow declined 19.31% from -$5.47M to -$6.53M, and EBIT declined 10.15% from -$5.9M to -$6.5M.
Metabolix, Inc. (MBLX) was downgraded to E+ from D- on 5/17/2016 due to a large decline in the growth index, valuation index and solvency index. The quick ratio declined from 3.27 to 1.87, operating cash flow declined 19.31% from -$5.47M to -$6.53M, and EBIT declined 10.15% from -$5.9M to -$6.5M.
D
Sell
3/11/2016Downgrade
Metabolix, Inc. (MBLX) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index and total return index.
Metabolix, Inc. (MBLX) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index and total return index.
OTC PK
04/01/2025 10:24AM Eastern
Quotes delayed
